You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Harvard Business School
Baxter
Colorcon
Medtronic

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,221,633

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,221,633
Title: Insulin derivatives having a rapid onset of action
Abstract:The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.
Inventor(s): Ertl; Johann (Bremthal, DE), Habermann; Paul (Eppstein, DE), Geisen; Karl (Frankfurt, DE), Seipke; Gerhard (Hofheim, DE)
Assignee: Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)
Application Number:09/099,307
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use; Formulation;

Drugs Protected by US Patent 6,221,633

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,221,633

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 26 167Jun 20, 1997

International Family Members for US Patent 6,221,633

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 015899   Start Trial
Austria 283919   Start Trial
Australia 7306498   Start Trial
Australia 740344   Start Trial
Brazil 9803708   Start Trial
Brazil PI9803708   Start Trial
Canada 2235443   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Harvard Business School
Moodys
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.